At new manufacturing department No. 5 launched in early 2021 there are productions lines for manufacture of both solid and injection dosage forms. The site possesses one of the most high-capacity production lines in Russia for manufacture of lyophilized products.

Grace to its high capacity equipment, the new department can produce up to 4 million tablets, 72 million vials of solutions and concentrates, and over 8 million vials of lyophilized products per year.

In general, in 2020 the share of the Pharmasyntez Group of Companies in the hospital procurements segment reached 7.3% in terms of volume, according to analytical agencies data.

The minister praised a vigorous growth of the company’s production capacities and high performance in implementing its investment projects.

“COVID-19 pandemic has shown us that it is crucial to have a domestic manufacture of major drug substances for the drugs that people need on a daily basis. We need to increase manufacture of high quality and efficient drugs for the treatment of COVID-19, tuberculosis, diabetes mellitus, hepatitis, and other serious diseases. Pharmasyntez has all the technological capabilities to do it. At the Irkutsk plant, the company has managed to promptly launch a manufacture of such anti-COVID drugs as Remdesivir and Favipiravir that are now supplied to all healthcare institutions of Russia,” the minister said.

“Thanks to the launch of manufacturing department No. 5, we will increase a finished product output at the Irkutsk plant in 2021 by 20% as compared with the previous year. The most up-to-date equipment is installed at the department which allows us to manufacture high quality drugs and to expand the range of drug products for years to come,” Olga Galkina, JSC Pharmasyntez Vice President for Manufacturing, noted.